Detalles de la búsqueda
1.
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
N Engl J Med
; 386(23): 2188-2200, 2022 06 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35443106
2.
Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
J Infect Dis
; 227(10): 1153-1163, 2023 05 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36683419
3.
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
J Infect Dis
; 228(8): 1055-1059, 2023 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37280116
4.
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
Clin Infect Dis
; 76(7): 1247-1256, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36411267
5.
Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma.
Cancer Immunol Immunother
; 71(5): 1167-1181, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-34623465
6.
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
Ann Rheum Dis
; 81(7): 951-961, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35338035
7.
The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases.
Int J Mol Sci
; 22(20)2021 Oct 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34681945
8.
Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer.
PLoS Genet
; 12(4): e1005895, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27093186
9.
Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma.
BMC Cancer
; 14: 131, 2014 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-24571613
10.
CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients.
Pediatr Transplant
; 18(2): 166-76, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24438215
11.
Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR Study.
Pulm Ther
; 10(1): 53-67, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38064153
12.
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.
Infect Dis Ther
; 13(6): 1253-1268, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38703336
13.
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.
Infect Dis Ther
; 13(3): 521-533, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38403865
14.
Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
Microbiol Spectr
; : e0033323, 2023 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36877050
15.
Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).
Infect Dis Ther
; 12(12): 2691-2707, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37914983
16.
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
Infect Dis Ther
; 12(9): 2269-2287, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37751015
17.
Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.
J Clin Pharmacol
; 62(9): 1094-1105, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35352835
18.
Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring.
Microbiol Spectr
; 10(5): e0103422, 2022 10 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35993765
19.
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.
JCI Insight
; 7(3)2022 02 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35132961
20.
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
Clin Cancer Res
; 28(17): 3709-3719, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35699623